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ABSTRACT 23 
Acute Myocardial Infarction with ST-segment elevation (STEMI) initiates with 24 
intraluminal thrombosis and results in total occlusion of the coronary artery. To date, 25 
characterization of the coronary thrombus proteome in STEMI patients has not been yet 26 
accomplished. Therefore, we aimed to perform an in-depth proteomic characterization 27 
of the coronary thrombus by means of three different approaches: 2-DE followed by 28 
mass spectrometry (MALDI MS/MS), 1-DE combined either with liquid 29 
chromatography coupled to mass spectrometry in a MALDI TOF/TOF (LC-MALDI-30 
MS/MS), or in a LTQ-Orbitrap (LC-ESI-MS/MS). This approach allowed us to identify 31 
a total of 708 proteins in the thrombus. Expression in human coronary thrombi (n=20) 32 
of 14 proteins was verified, and the expression of fibrin and 6 cell markers (platelets, 33 
monocytes, neutrophils, eosinohils, T-cells and B-cells) quantified by SRM. A positive 34 
correlation of 5 proteins (fermitin homolog 3, thrombospondin-1, myosin-9, beta parvin 35 
and ras-related protein Rap-1b) with CD41 was found, pointing out the activation of a 36 
focal adhesion pathway within thrombi platelets. DIDO1 protein was found to correlate 37 
negatively with thrombus fibrin, and was found up-regulated in the plasma of these 38 
STEMI patients, which constitutes an important starting point for further analyses in the 39 
search for biomarkers of thrombosis. 40 
Keywords: human coronary artery, acute myocardial infarction, focal adhesion, 41 
thrombosis, DIDO1. 42 
43 
INTRODUCTION 44 
ST-segment elevation myocardial infarction (STEMI) is caused by the rupture or 45 
the erosion of a vulnerable atherosclerotic plaque, initiating with intraluminal 46 
thrombosis and resulting in total occlusion of the coronary artery [1]. Several circulating 47 
cell types such as platelets, erythrocytes and monocytes, among others, as well as 48 
plasma molecules, modulate the final consequences of plaque disruption, contributing 49 
differently to the atherosclerotic process and therefore to subsequent thrombus 50 
formation [2, 3]. These circulating cells have been widely studied under different 51 
pathophysiological states [4,5] focusing on their cellular protein expression and their 52 
modifications during the development of cardiovascular episodes [3, 6]. In contrast, 53 
thrombus studies have been limited, mainly due to the difficult accessibility to the 54 
thrombotic material. Currently, the extraction of occlusive thrombi is achieved by an 55 
aspiration catheter, which is introduced in the coronary arterial tree. The use of this 56 
methodology has allowed obtaining coronary thrombi with acute phase characteristics 57 
from patients suffering from myocardial infarction [7]. The majority of studies 58 
performed in aspirated material are histological, based on the presence of different cell 59 
types in the coronary thrombus [8, 9] or the expression of different thrombosis-related 60 
proteins detected by immunohistochemistry (IHC) [10].  In a recent work, Silvain et al. 61 
studied composition of the coronary thrombus in STEMI patients by means of scanning 62 
electron microscopy. Results obtained highlighted a dynamic evolution of thrombi 63 
composition with ischemia time, with a significant decrease in platelet number and a 64 
significant increase in fibrin [11].  65 
The integrin alpha-IIb/beta-3 (CD41) is a receptor present in platelets, which 66 
binds fibronectin, plasminogen, prothrombin, thrombospondin and vitronectin, as well 67 
as fibrinogen and its cleavage product fibrin. CD41 is responsible for platelet 68 
aggregation and interaction with extracellular matrix (ECM) and other cells upon 69 
activation [12]. Although the role of platelets in thrombosis has been deeply 70 
characterized at the molecular level by means of numerous in vitro studies [13], the 71 
molecular mechanisms underlying platelet activation and focal adhesion within 72 
coronary thrombi have not been to date clearly elucidated. 73 
Concerning clinical proteomics, which main objective is identifying proteins 74 
involved in a disease in a defined biological system, the analysis of the protein content 75 
of the human coronary thrombus in the context of STEMI is still a pending issue. The 76 
proteomic methodology has been already applied to describe the proteome of 77 
platelets[14], erythrocytes [15] and monocytes [16] as well as to define protein profiles 78 
of such cells associated to acute coronary syndrome [3,6] and to characterize the 79 
proteome of the atherosclerotic plaque tissue [17,18]. The analysis of the thrombus 80 
proteome may reveal the contribution of the aforementioned described factors, involved 81 
in the atherothrombotic process leading to thrombus formation. Previous thrombi 82 
proteomic studies have been performed with cells isolated from venous thrombi [19] or 83 
have only focused on substances released by aortic artery thrombi [20]. Therefore, to 84 
date, no comprehensive proteomic characterization of the coronary thrombus has been 85 
conducted. The objective of the present study was to identify, through a global 86 
proteomics approach, the proteome of the coronary thrombus from patients with 87 
STEMI, as well as to build a 2-DE map of this sample, as a reference for future 88 
comparative studies. Moreover, 14 proteins were analyzed by SRM together with 6 cell 89 
markers (CD41, CD3, CD14, CD19, ELNE and PERE) and fibrin, and correlation 90 
analyses between all molecules allowed describing a novel methodology to link protein 91 
expression with cellular and ECM measures, therefore contextualizing protein changes 92 
with the addition of thrombus composition information.  93 
The coronary thrombus extracted just after a STEMI reflects the dynamic process 94 
triggered within the artery leading to myocardial infarction, thereby containing proteins 95 
locally expressed by the activated cells present, which may be released to the blood and 96 
that could have potential use as biomarkers. Hence, the protein DIDO1 was found up-97 
regulated in the plasma of these STEMI patients, which constitutes an important starting 98 
point for further analyses in the search for biomarkers of thrombosis. 99 
1.  MATERIALS AND METHODS 100 
1.1. Patient population and thrombus collection 101 
Twenty patients with STEMI were recruited at the Hemodynamic Service of 102 
Hospital Virgen de la Salud of Toledo within 12 hours of chest pain onset. By 103 
protocol all patients were pretreated with AAS and clopidogrel. Unfractioned 104 
heparin and Abxicimab© adjusted to body weight were used during examination in 105 
the catheterization laboratory. The occluded segment was crossed with hydrophilic 106 
wire and the patients were subjected to percutaneous intracoronary thrombectomy 107 
during primary angioplasty. Thrombectomy was performed with the 6F catheter 108 
Export (Medtronic Iberica). Aspirated blood and intracoronary thrombus material 109 
were collected in a collection bottle provided with a filter. Shortly after extraction, 110 
the thrombi tissue was cleaned with saline solution (0.9%) to reduce plasma 111 
contaminants. The aspirated thrombi material was equally divided in two fragments, 112 
one of which was embedded in OCT (Sakura Finetek USA Inc.; Torrance, CA) and 113 
the other one frozen and stored at -80ºC until used for proteomic analysis. This 114 
study was carried out in accordance with the recommendations of the Helsinki 115 
Declaration and it was approved by the ethics committee at the Hospital ―Virgen de 116 
la Salud‖ (Toledo, Spain). Signed informed consent was obtained from all subjects 117 
prior to their inclusion in the study. Clinical characteristics of selected patients are 118 
shown in Table 1. The first four thrombi were used for a comprehensive proteomic 119 
analysis of human coronary proteome and all twenty thrombi were employed for 120 
further analyses. 121 
EDTA coagulated plasma from 17 out of the 20 patients, and 16 healthy subjects 122 
with matched clinical characteristics (no significant differences were observed for 123 
age, gender and cardiovascular risk factors, Supplementary Table 1), was collected 124 
and stored at -80ºC until used. 125 
1.2. Histopathological analysis 126 
The four thrombi used for the characterization of human coronary thrombus 127 
proteome were subjected to histopathological analysis, in order to validate collection 128 
procedure. Aspirated material was embedded in OCT, serially cut in 5 µm and mounted 129 
on glass slides. The sections were stained with Hematoxilin and Eosin (H&E) for light 130 
microscopy. Immunohistochemical analysis was performed with antibodies against 131 
CD41, fibrinogen and neutrophil elastase (all from Abcam). After blocking non-specific 132 
reactions with 10% goat normal serum (Abcam), avidin 0.001% and biotin 0.001% in 133 
PBS-T 0.05%, sections were incubated with primary antibodies at room temperature 134 
(RT) for 1 hour. Secondary antibody conjugated with biotin, streptavidin-peroxidase 135 
and DAB used for all immunostainings was from Mouse and Rabbit Specific HRP/DAB 136 
(ABC) Detection IHC kit (Abcam).  137 
1.3. Protein extraction from thrombi 138 
Frozen aspirated thrombi were ground into a powder in liquid nitrogen with a 139 
mortar. An amount of 0.1-0.3 g of this powder was resuspended in 200 µL of protein 140 
extraction buffer (7M Urea, 2M Thiourea, 4% CHAPS, PMSF 1mM). The homogenate 141 
was sonicated 5 min, centrifugated at 21,000g (5840R Eppendorf) for 15min at 4ºC, and 142 
the supernatant was separated from the pellet of tissue debris. The protein concentration 143 
was determined by a Bradford-Lowry method (Bio-Rad protein assay).  144 
1.4. Unidimensional and two-dimensional gel electrophoresis (1-DE and 2-DE) 145 
An amount of 36 µg of a pool of protein extracts from 4 patients was loaded in 146 
10% SDS-polyacrylamide gels for unidimensional electrophoresis (1-DE). The lane in 147 
the 1-DE gel was divided into 10 gel slices that were manually excised for LC-MALDI-148 
MS/MS (Figure 1). For LC-ESI-MS/MS analysis, the electrophoresis was stopped when 149 
the sample had barely passed the resolution gel, so that it was concentrated in a unique 150 
band [21]. The band in the 1-DE gel was manually excised and afterwards digested.  151 
All chemicals and instruments used in 2-DE gels have been previously described 152 
[22]. Thrombi extracts were delipidated by adding ice-cold tri-n-butylphosphate: 153 
acetone: methanol (1:12:1) to a final acetone concentration of 80% and incubated at 4ºC 154 
for 90 min according to Leppeda et al. [18]. Precipitates were re-solubilized in the same 155 
extraction buffer by repeated sonications. An amount of 75 µg from each protein extract 156 
from the 4 patients was mixed and dialysed against 20 mM Tris buffer using Mini 157 
dialysis Kit 1kDa cut-off (GE Healthcare). Subsequently, 300 µg of the pooled protein 158 
extract was cleaned with 2-D Clean-up Kit (GE-Healthcare) and resuspended in 159 
rehydration buffer (7M Urea, 2M Thiourea, 4% CHAPS, 1% Ampholites and 1% TBP). 160 
Isoelectric focusing (IEF) was performed in a PROTEAN IEF Cell unit (Bio-Rad). The 161 
IPG strip (17cm and pH 4-7, Bio-Rad) was actively rehydrated at 20ºC for 12h at 50V 162 
to enhance protein uptake and then the voltage was increased according to the following 163 
program: 500 V for 1h, 1000V for 1h, 1000-8000V in 1h (gradient), 8000V for a total 164 
50.000V/h. Following IEF, IPG strips were equilibrated in 6 M urea, 50 mM Tris-HCl 165 
pH 8.8, 30% glycerol, 4% SDS, first with DTT (1% m/v) and subsequently with IAA 166 
(2.5% m/v), for 20 min.  Second dimension (SDS-PAGE in 12% polycarylamide gels) 167 
was performed in an Ettan Dalt Six system (GE Healthcare) overnight at 1W/gel and 168 
25ºC overnight. Gels were fixed and stained using Silver Staining kit (GE Healthcare) 169 
according to the manufacturer’s indications and they were then scanned with GS-800 170 
Calibrated Densitometer (Bio-Rad). 171 
1.5. Protein digestion  172 
The digestion of gel slices and spots was performed according to Schevchenko et 173 
al. [23] with minor modifications using the Ettan Digester (GE Healthcare): gel slices 174 
from 1-DE gel and spots excised from 2-DE gel were incubated with 10 mM DTT 175 
(Sigma Aldrich) in 50 mM ammonium bicarbonate (99% purity; Scharlau) for 30min at 176 
56ºC and after reduction, alkylation with 55 mM iodoacetamide (Sigma Aldrich) in 50 177 
mM ammonium bicarbonate was carried out for 20min at RT. Gel plugs were washed 178 
with 50 mM ammonium bicarbonate in 50% methanol (gradient, HPLC grade, 179 
Scharlau), rinsed in acetonitrile (gradient, HPLC grade, Scharlau) and dried in a 180 
Speedvac. Dry gel pieces were covered with sequencing grade modified porcine trypsin 181 
(Promega, Madison, WI, USA) at a final concentration of 20 ng/µL in 20 mM 182 
ammonium bicarbonate. After digestion at 37 ºC overnight, peptides were extracted 183 
with 60% acetonitrile (ACN) in 0.5% trifluoroacetic acid (99.5% purity; Sigma Aldrich) 184 
and dried in a Speedvac. The digested samples from 1-DE gel were resuspended in 185 
20µL [98% water with 2% trifluoroacetic acid and 2% ACN] for LC separation.  186 
1.6. MALDI-MS/MS analysis of 2-DE spots 187 
A volume of 0.5 μL from each 2-DE spot digestion solution was deposited using 188 
the thin layer method, onto a 384 Opti-TOF 123x81 mm MALDI plate (Applied 189 
Biosystems) and allowed to dry at room temperature. The same volume of matrix, 190 
3mg/mL α-cyano-4-hydroxycinnamic acid (CHCA, Sigma Aldrich) in 60% acetonitrile, 191 
0.5% trifluoroacetic acid, was applied on every sample in the MALDI plate. MALDI-192 
MS(/MS) data were obtained in an automated analysis loop using a 4800 Plus MALDI 193 
TOF/TOF Analyzer (Applied Biosystems). Automated analysis of mass data was 194 
performed using the 4000 Series Explorer Software version 3.5.3 (Applied Biosystems). 195 
MALDI-MS and MS/MS data were combined through the GPS Explorer Software 196 
Version 3.6 to search a nonredundant protein database (Swissprot 2011_11) using the 197 
Mascot software version 2.2 (Matrix Science), with 50 ppm precursor tolerance, 0.6 Da 198 
MS/MS fragment tolerance and carbamidomethyl cysteine as fixed modification, 199 
oxidized methionine as variable modification and allowing 1 missed cleavage. MALDI-200 
MS(/MS) spectra and database search results were manually inspected in detail using 201 
the previous software. For combined MS and MS/MS data, identifications were 202 
accepted when Confidence Interval (C.I.%) of GPS software was 95% or higher. For 203 
PMF spectra, identifications were accepted when (C.I.%) of GPS software was 99% or 204 
higher. 205 
1.7. LC- MALDI MS/MS analysis 206 
The peptides extracted from 1-DE gel were separated on an Ultimate
™
 nano-LC 207 
system (Dionex) using a Monolithic C18 column (Onyx, monolithic C18, 150 x 0.1 208 
mm, Phenomenex) at a flow rate of 300 nl/min in combination with a precolumn 209 
(Acclaim Pep Map 100 C18, 5 µm, 100Ǻ; 300µm id x 5 mm, LC Packings) at a flow 210 
rate of 30 µL/min. The buffers being used were: A = 0.1% TFA and B = 95% ACN with 211 
0.1% TFA. Peptides were desalted for 3 min with 0.1% TFA/5% ACN on the 212 
precolumn, followed by a separation for 90 min using gradient from 10% to 95% 213 
solvent B. Fractionation of the peptides was performed with a Probot
™
 microfraction 214 
collector (Dionex). CHCA (Sigma-Aldrich) was used as MALDI matrix. The contact 215 
start signal was send to the Probot after 10 min LC run time to start the fractionation. 216 
Fractions were colleted for 12s and spotted on a blank MALDI sample plate (Applied 217 
Biosystems) using a 32 x 52 geometry (1664 spots per plate). MS and MS/MS analysis 218 
of offline spotted peptide samples were performed using the Applied Biosystems 4800 219 
plus MALDI TOF/TOF Analyzer mass spectrometer. Peptide and protein identifications 220 
were performed using ProteinPilot
TM
 Software V 2.0.1 (Applied Biosystems) and the 221 
Paragon algorithm. Each MS/MS spectrum was searched against the SwissProt 2011_11 222 
database, with the fixed modification of carbamidomethyl cysteine parameter enabled. 223 
Other parameters such as the tryptic cleavage specificity, the precursor ion mass 224 
accuracy and the fragment ion mass accuracy, are MALDI 4800 built in functions of the 225 
ProteinPilot software. Although this software automatically accepts all peptides with an 226 
identification confidence level > 1%, only proteins having at least one peptide above the 227 
90% confidence level were initially recorded. Search against a concatenated database 228 
containing both forward and reversed sequences (decoy search) enabled the false 229 
discovery rate to be kept below 1%. 230 
1.8. LC-ESI-MS/MS data analysis  231 
Peptides were injected onto a C-18 reversed phase (RP) nano-column (100 µm 232 
I.D. and 12 cm, Mediterranea sea, Teknokroma) and analyzed in a continuous 233 
acetonitrile gradient consisting of 0-43% B in 140 min, 50-90% B in 1 min (B=95% 234 
acetonitrile, 0.5% acetic acid). A flow rate of 300 nl/min was used to elute peptides 235 
from the RP nano-column to a PicoTip™ emitter nano-spray needle (New Objective, 236 
Woburn, MA) for real time ionization and peptide fragmentation on an LTQ-Orbitrap 237 
XL ETD mass spectrometer (Thermo Fisher, San José, CA, USA). An enhanced FT-238 
resolution spectrum (resolution=60000) followed by the MS/MS spectra from most 239 
intense five parent ions were analyzed along the chromatographic run (180 min). 240 
Dynamic exclusion was set at 0.5 min. 241 
Tandem mass spectra were extracted and charge state deconvoluted by Proteome 242 
Discoverer version 1.0 (Thermo Fisher Scientific). All MS/MS samples were analyzed 243 
using Sequest (Thermo Fisher Scientific; version 1.0.43.2) and X! Tandem (The GPM, 244 
thegpm.org; version 2007.01.01.1). X! Tandem was set up to search a subset of the 245 
human database assuming the digestion enzyme trypsin. Sequest was set up to search 246 
human_ref.fasta, (39414 entries) assuming trypsin digestion. Sequest and X! Tandem 247 
were searched with a fragment ion mass tolerance of 0.80 Da and a parent ion tolerance 248 
of 10.0 ppm. Oxidation of methionine, acetylation of lysine and phosphorylation of 249 
serine, threonine and tyrosine were specified in Sequest and X! Tandem as variable 250 
modifications. Scaffold (version Scaffold_3_00_03, Proteome Software Inc., Portland, 251 
OR) was used to validate MS/MS based peptide and protein identifications.  Protein 252 
probabilities were assigned by the Protein Prophet algorithm. Protein identification was 253 
performed establishing protein and peptide probability greater than 99% and 95%, 254 
respectively. Proteins that contained similar peptides and could not be differentiated 255 
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. 256 
1.9. Bioinformatics analysis of identified proteins  257 
For a functional examination of the identified proteins, the list of 708 proteins 258 
identified was implemented on the on-line software David Bioinformatics Resources 6.7 259 
(NIH) [24] and Functional Annotation Tool was used to search for enriched Gene 260 
Ontology (biological process and molecular function) categories, as well as for pathway 261 
analysis, using KEGG Pathways database.  Functional annotation clustering was 262 
performed in order to avoid redundancy of enriched categories and pathways (data not 263 
shown). Functional annotation chart for each search and the proteins included in every 264 
group are provided in the supplementary material. 265 
1.10. SRM analysis of proteins in human coronary thrombi 266 
Protein samples were reduced with 100 mM DTT in 50 mM ammonium 267 
bicarbonate (Scharlau) for 30 min at 37ºC, and alkylated for 20 min at room 268 
temperature (RT) with 550 mM iodoacetamide in 50 mM ammonium bicarbonate. The 269 
proteins were then digested in 50 mM ammonium bicarbonate, 15% acetonitrile 270 
(Scharlau) with sequencing grade modified porcine trypsin at a final concentration of 271 
1:50 (trypsin:protein). After overnight digestion at 37 ºC, 2% formic acid (Sigma 272 
Aldrich) was added and the samples were cleaned with Pep-Clean spin columns (Pierce) 273 
according to the manufacturer’s instructions. Tryptic digests were dried in speed-vac 274 
and resuspended in 2% acetonitrile, 2% formic acid (FA) prior to MS analysis. 275 
The LC-MS/MS system consisted of a TEMPO nano LC system (Applied 276 
Biosystems) combined with a nano LC Autosampler coupled to a modified triple 277 
quadrupole (4000 QTRAP LC/MS/MS, Applied Biosystems). Three replicate injections 278 
(2 µg of protein in 4 µL) were performed per sample in the mobile phase A (2% 279 
ACN/98% water, 0.1% FA) at a flow rate of 10 µL/min for 5 min. Peptides were loaded 280 
onto a µ-Precolumn Cartridge (Acclaim Pep Map 100 C18, 5 µm, 100Å; 300 µm i.d. X 281 
5mm, LC Packings) to preconcentrate and desalt samples. Reversed-phase liquid 282 
chromatography (RPLC) was performed on a C18 column (Onyx Monolithic C18, 150 283 
x 0.1mm I.D., Phenomenex) in a gradient of phase A and phase B (98% ACN/2% 284 
water, 0.1% FA). The peptides were eluted at a flow rate of 300 nl/min in a continuous 285 
acetonitrile gradient: 2%-15% B for 2 min, 15%-50% B for 38 min, 50 to 90% B for 2 286 
min and 90% B for 3 min. Both the TEMPO nano LC and 4000 QTRAP system were 287 
controlled by Analyst Software v.1.4.2.  288 
Theoretical SRM transitions were designed using MRMpilot software v1.1 289 
(ABSciex), with the following settings: Enzyme = trypsin, missed cleavages = 0; 290 
modifications in peptide ≤ 3; charge states = +1 from 300 to 600 Da, +2 from 500 to 291 
2000 Da, +3 from 900 to 3000 Da, +4 from 1600 to 4000 Da, +5 from 2400 to 10000 292 
Da; studied modification = none; fixed modifications = carboxyamidomethylation; 293 
variable modifications = none; min. number of amino acids ≥ 5; max. number of amino 294 
acids ≤ 30; ignore multiple modification sites; 3 transitions per peptide (Supplementary 295 
Table 2). A pool containing a mixture of all the samples was digested as described 296 
previously and analyzed in the 4000QTrap using a MIDAS acquisition method that 297 
included the theoretical transitions. Transitions were selected when the three co-eluting 298 
peaks (corresponding to the three transitions of the same peptide) had a signal-to-noise 299 
ratio over 5 and the MS/MS data matched the theoretical spectrum for that peptide. 300 
Collision energy was optimized to obtain the maximum transmission efficiency and 301 
sensitivity for each SRM transition. Transitions monitored during individual sample 302 
analyses were acquired at unit resolution in both Q1 and Q3, with dwell times of 50 ms 303 
resulting in cycle times of 1.8 s. The IntelliQuan algorithm included in Analyst 1.4.2 304 
software was used to calculate the peptide abundance on the basis of peak areas after 305 
integration. 306 
1.11. Immunoaffinity depletion of the 14 most abundant proteins from 307 
plasma  308 
We used the MARS-14 column (Agilent Technologies) to remove the 14 most 309 
abundant proteins in plasma (human albumin, IgG, α1-antitrypsin, IgA, transferrin, 310 
haptoglobin, α2-macroglobulin, α1-acid glycoprotein, apo AI, apo AII, Ig M, 311 
transthyretin, C3 and 92–99% fibrinogens). Human plasma (20 μL) from STEMI 312 
patients (n=17) and controls (n=16) was five-fold diluted in ―Buffer A‖ (Agilent 313 
Technologies) and spun in a microfuge for 1min through a 0.22 μm spin filter tube at 314 
maximum speed (about 16,000 g). The sample was then injected into a 1200 series 315 
HPLC System (Agilent Technologies) and chromatography was performed according to 316 
manufacturer's instructions. After chromatography, the aliquots of the flow-through 317 
fractions containing low-abundance proteins were combined and desalted using 318 
centrifugal filter devices with a 3 kDa cut off (Amicon Ultra, Millipore). These samples 319 
were stored at −80 °C prior to analysis 320 
1.12. Detection of proteins in coronary thrombi and plasma by Western 321 
Blot (WB) 322 
Immunodepleted plasma samples from STEMI patients (n=17) and healthy 323 
controls (n=16) were resolved in 10% SDS-PAGE gels using a Bio-Rad Miniprotean 324 
Tetra Cell electrophoresis unit, run at a constant current of 25mA/gel for 1 h. Proteins 325 
were then transferred to a nitrocellulose membrane under constant voltage (12 V for 1 326 
h). Ponceau S staining was performed on the transferred membranes to ensure equal 327 
protein loading of the samples. The membranes were then blocked for 1h at RT with 328 
7.5% non-fat dry milk. All primary antibodies used were from Abcam (Rabbit 329 
polyclonal to Ferm3, ab68040; Mouse monoclonal to DIDO1, ab92868), and secondary 330 
antibodies were mouse and rabbit Trueblot, from eBiosciences. Blocked membranes 331 
were incubated 1h with the primary antibody in PBS-T containing 5% non-fat dry milk 332 
and then incubated with the specific HRP-conjugated secondary antibody in PBS-T 333 
containing 5% of non-fat dry milk. Detection was performed by enhanced 334 
chemiluminescence (ECL, GE Healthcare) following manufacturers’ instructions. 335 
1.13. Statistical analyses 336 
Packages SPSS 15.0 and GraphPad Prism were used for statistical analyses. WB 337 
bands were measured using a GS-800 Calibrated Densitometer (Bio-Rad) A 338 
Kolmogorov-Smirnov test demonstrated the normal distribution of the population 339 
analyzed. A Levene test for homogeneity of variance was performed and Student t-test 340 
was used for band intensity analysis. 341 
Correlations between proteins were evaluated by calculating Pearson product-342 
moment correlation coefficient of every transition from every peptide analyzed for each 343 
protein with respect to every transition of the peptides of the other proteins. If the 344 
results of 1 out of the 3 assayed transitions were divergent from the other two, this 345 
transition was not considered. While evaluating correlations, when 2 or more peptides 346 
were measured, the most significant peptide was selected, while the second one was 347 
used as a qualifier for the correlation, which was rejected if this second peptide had 348 
divergent results. Pearson´s correlation coefficient (r) was calculated as a mean of all 349 
coefficients from all transitions from the most significant peptide-to-peptide correlation. 350 
Correlation p value was expressed as <0,05; <0,01; <0,001 when all p values from all 351 
transitions from the most significant peptide-to-peptide correlation were lower than the 352 
specified values. When any of the transition-to-transition correlations was not 353 
significant, but close to signification, the greater transition-to-transition p value of the 354 
most significant peptide-to-peptide correlation was considered. For linear regression 355 
representation, the most significant transition was selected in each case. 356 
2. RESULTS 357 
 Three complementary proteomic approaches based on in-gel separation of 358 
proteins (2DE-MALDI-MS/MS) and on liquid-chromography separation of peptides 359 
(LC-MALDI-MS/MS and LC-ESI-MS/MS) were combined to perform a 360 
comprehensive characterization of the human coronary thrombus proteome, by 361 
analyzing a pool of 4 different thrombi from STEMI patients. 362 
2.1. Histology of thrombotic material 363 
H&E and immunostaining of thrombotic material allowed approving the 364 
collection procedure, since obtained tissue was composed of platelets (Figure 2C), 365 
erythrocytes (Figure 2B), fibrin (Figure 2D, see positive fibrin fibers and fibrinogen-366 
expressing platelets) and neutrophils (Figure 2E).  367 
2.2. 2-DE-MALDI-TOF/TOF 368 
Three technical replicates of human coronary thrombi gels were run showing 369 
minimal variability between runs, which confirmed reproducibility of the method. After 370 
PD-Quest software analysis (BioRad), more than 1000 spots were detected in coronary 371 
thrombi gels (Figure 3). An amount of 235 spots were excised from a 2-DE silver-372 
stained gel, digested and the resultant tryptic peptides were deposited in a MALDI 373 
plaque and analyzed in a 4800 Plus MALDI-TOF/TOF Analyzer (Applied Biosystem). 374 
All but 11 spots (224) were identified, corresponding to 81 unique proteins, 38 of which 375 
were represented by more than 1 spot (Figure 3). Supplementary Table 3 summarizes 376 
these identified proteins, their molecular weight, isoelectric point, subcellular location 377 
and function.  378 
 379 
2.3. Liquid-Chromatography Mass Spectrometry (LC-MS/MS) 380 
 381 
To improve the number of proteins identified by 2-DE MALDI-TOF/TOF, a LC-382 
MS/MS analysis was carried out using two different methodologies: 1-DE LC-MALDI-383 
MS/MS and LC-ESI-MS/MS.  384 
Using LC-MALDI-MS/MS approach, a total of 4,991 peptides were identified, 385 
which corresponded to 13,254 spectra. After data grouping and filtration, 372 proteins 386 
were identified (cut off >1.3 and >95% confidence interval, C.I.) and their theoretical 387 
MW and pI, subcellular location and function are shown in Supplementary Table 4.  388 
 389 
LC-ESI-MS/MS analysis allowed identifying a total of 2,520 unique peptides, 390 
which corresponded to 7,580 spectra. After data grouping and filtration, 467 proteins 391 
were identified (>95% C.I.) and their theoretical MW, subcellular location and function 392 
are shown in Supplementary Table 5.  393 
2.4. Characterization and classification of identified proteins 394 
A total of 708 unique proteins were identified with the three methodologies 395 
employed (Supplementary Table 6), 81 proteins corresponding to 235 spots were 396 
identified by 2-DE MALDI-TOF/TOF; 372 proteins by 1-DE LC-MALDI-MS/MS and 397 
467 proteins by LC-ESI-MS/MS. Venn diagram showing the number of proteins 398 
identified by these methods can be observed in Figure 4A. The 138 proteins identified 399 
by both LC-MS/MS approaches and the 46 identified by all methodologies are compiled 400 
in Suplementary Table 4. 401 
Proteins were categorized in seven functional groups (Figure 4B); ―Cell 402 
differentiation‖, ―Metabolism‖, ―Redox State and Apoptosis‖, ―Regulation and 403 
transport‖, ―Immune response and acute phase‖, ―Structural and cell adhesion‖ and 404 
―Other‖, based on NCBI and UniProt data base information. Furthermore, the proteins 405 
were also classified by their subcellular location (Figure 4C).  406 
Functional analysis performed with David 6.7 software for Gene Ontology (GO) 407 
categories ―molecular function‖ and ―biological process‖ reported a significant 408 
enrichment of cytoskeleton proteins. Other enriched GO categories were: ―Blood 409 
coagulation‖, ―Response to wounding‖, as well as ―Nucleotide binding‖, which showed 410 
a substantial contribution of ―ATP binding‖ proteins (105 out of the 163 proteins) 411 
(Supplementary Figure 1). On the other hand, remarkable pathways found enriched in 412 
the protein list were ―Regulation of actin cytoskeleton‖, ―Focal adhesion‖ (Figure 5), 413 
―Tight junction‖, ―Gap junction‖, ―Adherens junction‖, ―Leukocyte transendothelial 414 
migration‖, ―Glycolysis/gluconeogenesis‖ and ―Coagulation cascade‖ (Supplementary 415 
Figure 2). 416 
2.5. Protein expression and cellular composition analyses of human coronary 417 
thrombi 418 
A subset of 14 proteins identified by at least 2 out of the 3 proteomic approaches, 419 
with functional relevance for thrombus formation, were selected for further analyses: 420 
fermitin family homolog 3 (FERM3), death-inducer obliterator 1 (DIDO1), flavin 421 
reductase (NADPH), carbonic anhydrases 1, 2 and 3, calreticulin, catalase, multimerin-1 422 
(MMRN1), myosin-9 (MYH9), beta-parvin (PARVB), ras-related protein Rap-1b 423 
(RAP1B), titin and thrombospondin-1 (TSP1). This proteins were analyzed by SRM in 424 
all the collected thrombi (n=20) together with 6 cell markers: CD41 (platelets), CD3 (T 425 
lymphocytes), CD14 (monocytes), CD19 (B lymphocytes), neutrophil elastase and 426 
eosinophil peroxidase; and fibrin (analyzed peptides and transitions are displayed in 427 
Supplementary Table 2). Optimization experiments performed with a pool of all 20 428 
samples allowed detecting all proteins, verifying its expression within the human 429 
coronary thrombus of STEMI patients (chromatographic peaks of every transition are 430 
provided in Supplementary Figure 3). Every protein was quantified using 3 transitions 431 
of 2 peptides, except for fibrin (3 peptides: 2 of chain A, 1 of chain B), CD3 (3 peptides: 432 
2 of chain gamma and 1 of chain delta), and CD14 and FERM3, in which only 1 peptide 433 
could be measured. Moreover, correlation analyses between all studied proteins were 434 
performed, in order to link protein expression of the analyzed proteins with the cell and 435 
ECM (fibrin) markers. Significant and close to significance correlations are displayed 436 
on Supplementary Table 7. 437 
Concerning cell markers evaluated, T-cell marker CD3 correlated positively with 438 
monocyte and B-cell markers (CD14: r=0.98; p value<0.001 and CD19: r=0.57; p 439 
value<0.05). A negative correlation of ELNE with CD3 (r=-0.49; p value<0.05) and 440 
CD14 (r=-0.49; p value<0.05) was also found. A positive correlation was found for 441 
ELNE with PERE (r=0.68; p value<0.01). A positive correlation of CD14 with CD19 442 
was close to signification (r=0.42; p value<0.097). 443 
A group of 5 proteins were found to correlate positively with the platelet marker 444 
CD41: FERM3 (r=0.94; p value<0.001), MYH9 (r=0.89; p value<0.001), TSP1 (r=0.96; 445 
p value<0.001) PARVB (r=0.96; p value<0.01) and RAP1B (r=0.95; p value<0.001) 446 
(Figure 6A). Furthermore, all these proteins showed a positive correlation with the other 447 
4 proteins, with a Pearson's coefficient above 0.76 and a p value < 0,001 448 
(Supplementary Table 7). Multimerin-1 (MMRN1) was found to correlate positively 449 
with neutrophil and eosinophil markers (ELNE: r=0.98; p value<0,001); PERE: r=0.66; 450 
p value<0.01) and negatively with CD3 (r=-0.52; p value<0.05). A negative correlation 451 
with monocytes very close to signification was also found (r=-0.42; p value<0.08). 452 
Fibrin showed a negative correlation with DIDO1 (r=-0.50, p value<0.05; Figure 453 
6B), and a positive correlation with TSP1 (r=0.63; p value<0.01) and PARVB (r=0.61; 454 
p value<0.01).    455 
2.6. Plasma analyses of DIDO1 and FERM3 456 
In order to study a potential reflection of the expression of these proteins within 457 
thrombi with an increase of their circulating levels, DIDO1 and FERM3 proteins were 458 
analyzed by WB in immunodepleted plasma from STEMI patients versus healthy 459 
subjects. FERM3 showed a moderate non-significant increase in the plasma of STEMI 460 
patients (p value = 0.34, Supplementary Figure 4B). DIDO1 WB of immunodepleted 461 
plasma showed 4 reactive bands for this protein, ranging from 60 kD (molecular weight 462 
of DIDO1 isoform 2, which corresponds to the so-called DIDO1 species) to 40 kD 463 
(Figure 6C). Previous optimization WB analyses performed platelet extracts also 464 
showed a variety of protein species from DIDO1 (Figure 4A), which could correspond 465 
to physiologically generated cleavage products.   466 
After quantification, the 60kDa DIDO1 band was found up-regulated in the 467 
plasma of STEMI patients (T-test p-value = 0.024). Moreover, total protein amount of 468 
DIDO1, calculated as sum off all detected bands, was significantly increased in the 469 
plasma from STEMI patients (T-test p-value = 0.036, Figure 6D). 470 
 471 
3. DISCUSSION 472 
Understanding the nature of the complex biological processes present in a tissue 473 
or organism requires an in-depth analysis at the molecular level, in the search for key 474 
proteins involved. In this sense, the characterization of the proteome of the human 475 
coronary thrombus may be a fundamental key to elucidate the mechanisms involved in 476 
its formation and it might help us to understand the plaque rupture process leading to 477 
acute myocardial infarction.  478 
In the present study we aimed to describe the protein content of coronary 479 
thrombus, employing three proteomic approaches (2-DE MALDI-MS/MS, 1-DE LC-480 
MALDI-MS/MS and LC-ESI-MS/MS). On the other hand, we provide for the first time 481 
a protocol for analyzing by SRM, in a single method, a sub-group of proteins of interest, 482 
and cellular (CD41, platelets; CD3, T lymphocytes; CD14, monocytes; CD19, B lymphocytes; 483 
neutrophil elastase and eosinophil peroxidase) and ECM biomarkers (fibrin) in thrombotic 484 
material, with the possibility to contextualize expression changes with thrombus 485 
composition. Furthermore, the detection of 14 proteins by SRM analysis not only 486 
represents a validation of the thrombus characterization methodology performed, but 487 
also points out the implication of such molecules in human coronary thrombus 488 
formation.  489 
A total number of 708 proteins were identified within the human coronary 490 
thrombus. The three different approaches performed have been proved to be 491 
complementary, since each method exclusively identified a subset of proteins, which 492 
were not found by the other two (Figure 4A). Although the 2-DE approach usually 493 
yields less number of identified proteins of a complex proteome than LC-based 494 
approaches, provides valuable information of observed molecular weight and isoelectric 495 
point, and potential posttranslational modifications. LC-MS/MS methodologies allowed 496 
identifying 138 common proteins, which could be considered as a ―core proteome‖ of 497 
the human coronary thrombus from STEMI patients as a reference for future studies in 498 
the field.  499 
Identified proteins were classified in seven different functional groups: ―Cell 500 
differentiation‖, ―Metabolism‖, ―Redox state and apoptosis‖, ―Regulation and 501 
transport‖, ―Immune response and acute phase‖, ―structural and cell adhesion‖, and 502 
―Other‖. The groups ―Structural and cell adhesion‖ and ―Regulation and transport‖ have 503 
a remarkable significance considering the percentage of proteins present in the 504 
thrombus. Both groups represent 62% of the total thrombus protein content, in which 505 
―cytoskeleton‖ and ―intracellular signalling‖ proteins have a major contribution. 506 
Moreover, functional analysis performed using David 6.7 revealed a significant 507 
enrichment of ―cytoskeleton‖ proteins in the thrombus, when Gene Ontology terms for 508 
molecular function and biological process were selected (Supplementary Figure 1). 509 
Pathway analysis using KEGG Database pointed out an outstanding implication of these 510 
proteins in focal adhesion (Figure 5) and various types of cell junctions related to cell-511 
cell and cell-matrix interactions (Supplementary Figure 2).  512 
The group ―Structural and cell adhesion‖ is represented both by cell membrane 513 
and cytoplasmic proteins. Among these identified proteins, a wide variety of integrins 514 
were found, like integrin alpha-IIb (CD41), which have a determinant role in platelet 515 
formation and activation [12]. Besides, correlation analyses showed a co-expression of a 516 
subset of 5 proteins (FERM3, MYH9, TSP1, PARVB and RAP1B) with the platelet 517 
marker CD41, which are indeed implicated in the aforementioned focal adhesion 518 
pathway (proteins are highlighted in red in Figure 5). TSP1 is a matricellular protein 519 
and a major component of α-granules from platelets, which is released upon their 520 
activation [25]. After its release by platelets, contributes to cell adhesion through 521 
binding the integrins that mediate platelet/platelet and platelet/matrix interactions (i.e. 522 
CD41) [26]. Fermitin family homolog 3 (also called kindlin-3) is involved in adhesion 523 
of hematopoietic cells, especially platelets [27], and regulates NF-kappa B expression 524 
and cell apoptosis [28]. Although its expression by platelets, hereby corroborated by 525 
SRM, has been found in a mouse model to be essential for aggregation and integrin 526 
activation [27], there were no previous evidences of the implication of this protein in 527 
platelet activation leading to thrombus formation. WB of immunodepleted plasma 528 
allowed detecting this protein and showed a moderate increase in STEMI patients, 529 
although statistical analysis did not find significant results.  530 
Beta parvin is an integrin-linked kinase (ILK) binding protein which modulates 531 
intracellular signalling mediated by ILK, therefore controlling cell adhesion, cell 532 
spreading, establishment or maintenance of cell polarity, and cell migration [29, 30]. 533 
This protein has been proved to be essential for platelet adhesion and spreading [31], 534 
but hereby we report for the first time its direct implication in such processes within the 535 
human thrombus. Myosin-9 plays an important role in cytoskeleton reorganization, 536 
focal adhesion and lamellipodial retraction during cell spreading [32]. Disruption of this 537 
protein in mice showed a strong impair of thrombus growth and organization [33], 538 
which is consistent with our results pointing out an outstanding role of MYH9 in 539 
platelet activation during human coronary thrombus formation.  540 
The first functional group in terms of number of proteins present is ―Regulation 541 
and transport‖, which is composed of several G-proteins and Ras-related proteins, 542 
protein families deeply involved in signal transduction. Functional analysis therefore 543 
reported a significant enrichment of nucleotide binding proteins in the thrombus 544 
proteome, corresponding to intracellular trafficking and ATP modulating molecules. 545 
Among this group, ras-related protein Rap-1b participates to the conversion of integrins 546 
into a high-affinity state for their ligands, that in turn favors platelet/platelet and platelet 547 
/ECM interaction [34], and its implication in thrombosis has been proved in several in 548 
vivo animal models [35,36]. Though, in this work we provide evidences of the 549 
participation of RAP1B in platelet aggregation and adhesion to ECM within the 550 
coronary thrombus. 551 
This sub-group of adhesion proteins co-expressed with CD41 might be expressed 552 
at early stages of thrombus formation, since platelet number decreases with ischemia 553 
time, as reported by Silvain et al. [11]. Further analyses are needed to establish a direct 554 
connection of these proteins with ischemia time. 555 
Multimerin-1 acts as a carrier for coagulation factor V and it is stored by platelets 556 
in the α-granules [37]. After released by these granules upon activation, MMRN1 is key 557 
to platelet aggregation and thrombus formation, as reported in mice studies [38]. Our 558 
results show a positive correlation of MMRN1 with both neutrophils and eosinophils 559 
and a negative correlation with monocytes (close to signification, r= -0.42; p 560 
value<0.088) and T-cells, but surpsisingly no correlation with platelet number was 561 
found. MMRN1 has been reported to be expressed by human leukocytes [39] but is 562 
mainly expressed by platelets and determinant in their aggregation and adhesion with 563 
neutrophils and endothelial cells [37, 40] (the protein is highlighted in blue in Figure 5). 564 
Although correlation of MMRN1 levels with neutrophil and eosinophil cell number 565 
could be explained by a specific expression of this protein by these cell types, reported 566 
expression of MMRN1 by leukocytes is minoritary and may not have driven such 567 
protein changes. Otherwise, release of MMRN1 by platelet α-granules may be triggered 568 
by neutrophils and/or eosinophils due to cytokine activation. Whether MMRN1 release 569 
is activated by such cells or not, activated neutrophils adhere to this protein [40], and 570 
thus expression of MMRN1 within the thrombus may provoke recruiting of neutrophils, 571 
which may account for the observed positive correlation. Hence, eosinphils may also be 572 
recruited by MMRN1. On the other hand, monocyte and T-cell infiltrate may inhibit 573 
MMRN1 expression in the coronary thrombus, although there is no evidence of such 574 
mechanism in the literature and further analyses should be performed to prove this 575 
hypothesis. 576 
The functional group ―Metabolism‖ is mainly constituted by proteins implicated 
577 
in energy metabolism. Pathway analysis also reported a significant enrichment of 
578 
proteins from the metabolic route of Glycolisis/Gluconeogenesis. An important 
579 
abundance of such proteins within the thrombus may come from an important 
580 
contribution of this route to the energetic need triggered by the thrombotic process and 
581 
the recruitment of circulating cells during its development [41]. Moreover, ATP binding 
582 
proteins are significantly enriched in thrombus proteome, according to the functional 
583 
analysis performed. The expression of a sub-group of enzymes implicated in redox 
584 
activity, identified in the proteomic characterization of human coronary thrombus 
585 
(carbonic anhydrases 1, 2 and 3; and flavin reductase (NAPDH)) was validated by SRM 
586 
analysis in the studied thrombi. No correlation of this proteins with cell markers was 
587 




Concerning cell markers evaluated by SRM, infiltrated monocytes, T-cells and B-
590 
cells are simultaneously present within the thrombus, as stated by correlation analyses. 
591 
Besides, neutrophils and eosinophils also co-localize in the human coronary thrombus. 
592 
On the other hand, there is a negative correlation of neutrophils with monocytes and 
593 
CD3, which may highlight a distinct infiltration pattern of both co-localizing sub-groups 
594 
of leukocytes. A negative correlation of fibrin with CD3 was found, which may indicate 
595 
a decrease of T-cells in older thrombi, since fibrin increases with ischemia time [11]. 
596 
Other subset of proteins of interest, due to their implication in the thrombotic 597 
process, is the one related to ―Redox state and apoptosis‖. Among these, catalase and 598 
DIDO1 were analyzed by SRM to verify their expression in the thrombus and in the 599 
search for correlations with cell markers and fibrin. DIDO1 is a pro-apoptotic 600 
transcription factor [42], which has not been previously reported to express in platelets, 601 
erythrocytes or blood plasma (according to HPRD database, www.hprd.org). WB 602 
analysis of platelet extract allowed verifying its actual expression by this cell type 603 
(Supplementary Figure 4A). Both WB and SRM analyses showed the expression of this 604 
protein during thrombogenesis. Moreover, a significant negative correlation of DIDO1 605 
with fibrin was found (Figure 6B), which highlights a role of this protein in the early 606 
stages of thrombus development, since contribution of fibrin to thrombus composition 607 
increases with ischemia time [11]. Besides, DIDO1 was found up-regulated in the 608 
plasma of these STEMI patients. This result shows a direct relation between the human 609 
coronary thrombus expression of DIDO1 and increased levels of such protein in the 610 
plasma of these STEMI patients. This may therefore imply a release of the protein by 611 
the thrombus to the bloodstream, which may be useful for diagnostic purposes. 612 
Study limitations 613 
It is important to note that these results were performed with aspirated material 614 
obtained during angioplasty and it is unclear to what extent this can be 615 
reliable/representative of the actual composition of a coronary thrombus, since 616 
aspiration of the thrombus may affect its protein content (51). On the other hand, drug 617 
anticoagulant therapies applied previous to angioplasty (pretereatment with ASA, 618 
clopidogrel in all patients) could also modify the thrombus proteome.  619 
Preliminary results obtained for plasma levels of DIDO1, pointing to an up-620 
regulation of this protein with STEMI are promising but need to be further validated in 621 
a greater cohort of patients.  622 
4. CONCLUSSIONS 623 
The data hereby presented provide an in-depth characterization of the human 624 
coronary thrombus of STEMI patients and contributes to a better understanding of the 625 
mechanisms involved in the activation processes of platelets and other cell types 626 
implicated in thrombus formation leading to acute coronary syndrome. Moreover, the 627 
expression of DIDO1 within the human coronary thrombus has been associated with an 628 
increase of its plasma levels, which constitutes an important starting point for further 629 
quantification analyses of the proteins described in this work in the search for 630 
biomarkers of thrombosis.  631 
5. ACKNOWLEDGMENTS 632 
This work was supported by grants from the Instituto de Salud Carlos III (FIS 633 
PI070537, PI11/02239), Fondos Feder, Redes temáticas de Investigación Cooperativa 634 
en Salud (RD12/0042/0071, RD06/0014/1015), and Fundación para la Investigación 635 
Sanitaria de Castilla-La Mancha (FISCAM PI2008-08, PI2008-28, PI2008-52). These 636 
results are lined up with the Spanish initiative on the Human Proteome Project 637 
(SpHPP). The CNIC is supported by the Spanish Ministerio de Economia y 638 
Competitividad and the Fundacion Pro-CNIC. We would like to thank Gemma Barroso 639 
from Proteomic Unit, Hospital Nacional de Paraplejicos, for her help and dedication to 640 
this work, as well as Veronica Moral and Ana Gallardo from the same Unit, and Tamara 641 
Sastre and Carmen Bermudez for their technical support.  642 
The authors have declared no conflicts of interests. 643 
FIGURE AND TABLE LEGENDS 644 
Figure 1. Flowchart showing the strategy applied for STEMI patients coronary thrombus 645 
characterization. 646 
Figure 2. Representative histological analysis of coronary thrombus obtained by intracoronary 647 
thrombectomy.  A, Low-augment view of a coronary thrombus (hematoxylin and eosin [H&E] 648 
stain). B, Detail of panel A showing H&E stain showing platelets, fibrin, erythrocytes and 649 
nucleated cells. C, Immunostaining with anti-CD41 antibody showing platelet presence in the 650 
thrombus. D, Immunostaining with anti-fibrinogen showing fibrin fibers and fibrinogen positive 651 
platelets. E, Neutrophil eleastase immunohistochemistry shows neutrophil infiltrate within the 652 
thrombus. 653 
Figure 3. Representative 2-DE gel image from pooled human coronary thrombi. The analysis 654 
was performed with 17cm IPG strip, pH 4-7 and SDS-PAGE 12% gels. Numbers correspond to 655 
the identified spots, as represented in Supplementary Table 3. 656 
Figure 4. Characterization of the identified proteins. A, Venn diagram showing the number of 657 
common/exclusive proteins identified by every proteomic method. Functional classification (B) 658 
and Subcellular location (C) of identified proteins. 659 
Figure 5. Focal adhesion pathway and proteins with significant correlation. Focal adhesion 660 
pathway was found significantly represented on the thrombus proteome by pathway analysis 661 
performed with David Bioinformatics Resources 6.7 (NIH).  662 
Symbols: , proteins present and pathways significantly enriched in the thrombus proteome. 663 
, molecular interaction or relation. , indirect effect. ―|, inhibition. +p, phosphorylation, 664 
-p, dephosphorylation. A positive correlation of proteins highlighted with a red rectangle with 665 
CD41 was found. FERM3 is not a constituent of this KEGG Database pathway, but it is of the 666 
platelet activation one, and directly interacts with CD41 to induce platelet focal adhesion and 667 
therefore it was included in the represented scheme.  Multimerin-1 (blue rectangle) was found to 668 
positively correlate with neutrohils and eosinophils. (Modified from KEGG Pathways Database, 669 
Kanehisa Laboratories) 670 
Figure 6. Expression analyses and correlation with thrombus composition. Fourteen proteins 671 
were analyzed by SRM together with 6 cell markers and the ECM marker fibrin. A, Correlation 672 
analyses showed a positive correlation of 5 proteins associated with focal adhesion and platelet 673 
activation with CD41 (platelet marker): FERM3 (r=0.94; p value<0.001), MYH9 (r=0.89; p 674 
value<0.001), TSP1 (r=0.96; p value<0.001) PARVB (r=0.96; p value<0.01) and RAP1B 675 
(r=0.95; p value<0.001)). These proteins were all correlated with the other four too. B, A 676 
negative correlation of DIDO1 protein with fibrin was also found (r=-0.50, p value<0.05). C, 677 
Abundance of DIDO1 was investigated in plasma from the same STEMI patients from the 678 
thrombus analysis (STEMI: n=17, lanes 4-6, 10-12; control: n=16, lanes 1-3, 7-10). Both the 679 
complete protein of approximately 60kDa (dta not shown, pvalue=0.024) and the sum of all 680 
bands (D, pvalue=0.036) observed (which may correspond to cleavage products of this protein) 681 
were over-expressed in STEMI patients' plasma, as observed after densitometry. OD*mm
2
, 682 
optical density per square millimetre. 683 
Table 1. Clinical characteristics of STEMI patients recruited for human coronary thrombus 684 
proteomic analysis. 685 
686 
SUPPLEMENTARY FIGURE AND TABLE LEGENDS  687 
Supplementary Figure 1. Summarized charts of David Bioinformatics Resources 6.7 688 
software (NIH) analyses performed with the 708 proteins identified for Gene Ontology 689 
categories ―molecular function‖ and ―biological process‖. 690 
Supplementary Figure 2. Most relevant functional pathways found significantly enriched in 691 
human coronary thrombus proteome after bioinformatic analysis with David Bioinformatics 692 
Resources 6.7 software.  693 
Supplementary Figure 3. Extracted ion chromatograms of every peptide analyzed by SRM in 694 
the optimization experiments, with its 3 monitored transitions. 695 
Supplementary Figure 4. A, Western Blot analysis of DIDO1 showing specific expression by 696 
platelets, with isoforms ranging from 65 kDa to 40 kDa. B, Western Blot analysis of FERM3 in 697 
immunodepleted plasma from STEMI patients versus healthy subjects. A moderate non- 698 
significant increase in STEMI patients can be observed (p value = 0.34). 699 
Supplementary Table 1. Clinical characteristics of healthy controls employed for plasma 700 
Western Blot analysis. 701 
Supplementary Table 2. Peptides and transitions used for SRM analysis of 14 proteins, 6 cell 702 
markers and fibrin. 703 
Supplementary Table 3. Spots identified in 2-DE gel (pH: 4-7). Showing: accession number, 704 
theoretical and experimental isoelectric point and molecular weight, subcellular location 705 
(Cellular membrane: Cell mb; Cytoplasm: Cp; Nucleus: N; Nuclear membrane: N mb; 706 
Mitochondrial inner membrane: Mit inn mb; Secreted: Sec; Mitochondria: Mit; Extracellular 707 
space: ES; Melanosome: Mel; Peroxisome: Per; Lysosome: Lys; Golgi apparatus: Gol app; 708 
Endoplasmic Reticulum: ER; Podosome: Pod; Extracellular Matrix: EM) and primary function. 709 
Supplementary Table 4. Proteins identified by 1-DE LC-MALDI-MS/MS. Showing: accession 710 
number, theoretical isoelectric point and molecular weight, subcellular location (Cellular 711 
membrane: Cell mb; Cytoplasm: Cp; Nucleus: N; Nuclear membrane: N mb; Mitochondrial 712 
inner membrane: Mit inn mb; Secreted: Sec; Mitochondria: Mit; Extracellular space: ES; 713 
Melanosome: Mel; Peroxisome: Per; Lysosome: Lys; Golgi apparatus: Gol app; Endoplasmic 714 
Reticulum: ER; Podosome: Pod; Extracellular Matrix: EM) and primary function. 715 
Supplementary Table 5. Proteins identified by LC-ESI-MS/MS. Showing: accession number, 716 
theoretical molecular weight, subcellular location (Cellular membrane: Cell mb; Cytoplasm: Cp; 717 
Nucleus: N; Nuclear membrane: N mb; Mitochondrial inner membrane: Mit inn mb; Secreted: 718 
Sec; Mitochondria: Mit; Extracellular space: ES; Melanosome: Mel; Peroxisome: Per; 719 
Lysosome: Lys; Golgi apparatus: Gol app; Endoplasmic Reticulum: ER; Podosome: Pod; 720 
Extracellular Matrix: EM) and primary function. 721 
Supplementary Table 6. Unique proteins identified by the 3 proteomic approaches, proteins 722 
identified by both LC-MS/MS methods and subset identified by all 3 methods. Showing: 723 
accession number, molecular weight, subcellular location (Cellular membrane: Cell mb; 724 
Cytoplasm: Cp; Nucleus: N; Nuclear membrane: N mb; Mitochondrial inner membrane: Mit inn 725 
mb; Secreted: Sec; Mitochondria: Mit; Extracellular space: ES; Melanosome: Mel; Peroxisome: 726 
Per; Lysosome: Lys; Golgi apparatus: Gol app; Endoplasmic Reticulum: ER; Podosome: Pod; 727 
Extracellular Matrix: EM) and primary function. 728 
Supplementary Table 7. Pearson´s correlation coefficient and p value of all the significant and 729 
close-to-significance correlations found. 730 
731 
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Troponin I (μg/ml) 16.9±26.6
CK (IU/ml) 997.1±1434.7
Troponin I maximum (μg/ml) 121.7±101.8
CK maximum (IU/ml) 4167.4±7314.3
Fibrinogen (g/l) 4.0±1.4
Platelets, mm3 202.3±60.3
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